Galera Therapeutics Announces ASTRO Late-Breaker Presentation of Topline Safety and Efficacy Data from its Double-Blind, Placebo-Controlled Phase 1b/2a Clinical Trial of GC4419 in Combination with SBRT for Locally Advanced Pancreatic Cancer
Company Updates Guidance for Topline Data Readout to ASTRO 2020
MALVERN, Pa., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), is a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of
novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer. Today, Galera announced that data from its double-blind, placebo-controlled pilot Phase 1b/2a clinical
trial of avasopasem manganese (GC4419) in combination with stereotactic body radiation therapy (SBRT) for locally advanced pancreatic cancer has been selected for presentation during the
Late-breaking Special Session at the 2020 ASTRO Annual Meeting, which is taking place virtually October 25-28, 2020. GC4419 is an investigational, highly selective small molecule superoxide
dismutase mimetic designed to rapidly and selectively convert superoxide to hydrogen peroxide and oxygen.
Details of the presentation are as follows:
Abstract Title: “Randomized, Double-Blinded, Placebo-controlled Multicenter Adaptive Phase 1-2 Trial of GC4419, a Dismutase Mimetic, in Combination with High Dose Stereotactic Body
Radiation Therapy (SBRT) in Locally Advanced Pancreatic Cancer (PC)”
Session Title: SS 19 – Late-breaking Special Session
Session Date: Tuesday, October 27, 2020
Session Time: 3-4:15 p.m. EDT
Presenter: Cullen Taniguchi, MD, MD Anderson Cancer Center
For more information about the 2020 ASTRO Annual Meeting, please visit https://www.astro.org/Meetings-and-Education/Micro-Sites/2020/Annual-M ....
Lesen Sie auch
About GC4419 (Avasopasem Manganese)
Galera’s lead product candidate, avasopasem manganese, is an investigational, highly selective small molecule superoxide dismutase (SOD) mimetic that is initially being developed for the reduction
of radiation-induced severe oral mucositis (SOM), which is not yet approved. Avasopasem is designed to rapidly and selectively convert superoxide to hydrogen peroxide and oxygen, protecting normal
tissue from damage associated with radiation therapy. Left untreated, elevated superoxide can damage noncancerous tissues and lead to debilitating side effects, including oral mucositis (OM), which
can limit the anti-tumor efficacy of radiation therapy.